METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS
AssigneeThe McLean Hospital Corporation
InventorsKwang-Soo Kim, Yongwoo Jang, Chun-Hyung Kim
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR-mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR activity and/or levels in a cell.
Claims33
A method of treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof, the method comprising administering to the subject at least one of:
- prostaglandin E (PGE) 1;
- PGE2:
- PGE3;
- prostaglandin H(PGH)1;
- PGH2;
- PGH3;
- prostaglandin F (PFG)2a;
- prostaglandin A (PGA)1;
- PGA2;
- PGA3;
- prostaglandin B (PGB)1;
- PGB2;
- PGB3;
- PGJ2;
- 15-d-PGJ2;
- and/or carbocyclic TxA2.
A method of increasing the level and/or activity of Nurr1 or PPARγ in a cell, the method comprising contacting the cell with at least one of:
- PGE1;
- PGE2:
- PGE3;
- PGH1;
- PGH2;
- PGH3;
- PGF2a;
- PGA1;
- PGA2;
- PGA3;
- PGB1;
- PGB2;
- PGB3;
- PGJ2;
- 15-d-PGJ2;
- and/or carbocyclic TxA2
A method of treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof, the method comprising administering to the subject a vector comprising a nucleic acid sequence encoding a Nurr1 polypeptide.
A method of treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof, the method comprising administering to the subject at least one of:
- prostaglandin E (PGE) 1;
- PGE2:
- prostaglandin H(PGH)1;
- PGH2;
- PGH3;
- prostaglandin F (PFG)2a;
- prostaglandin A (PGA)1;
- PGA2;
- PGA3;
- prostaglandin B (PGB)1;
- PGB2;
- PGB3;
- PGJ2;
- 15-d-PGJ2;
- and/or carbocyclic TxA2.
A composition comprising at least one of:
- prostaglandin E (PGE) 1;
- PGE2:
- PGE3;
- prostaglandin H(PGH)1;
- PGH2;
- PGH3;
- prostaglandin F (PFG)2a;
- prostaglandin A (PGA)1;
- PGA2;
- PGA3;
- prostaglandin B (PGB)1;
- PGB2;
- PGB3;
- PGJ2;
- 15-d-PGJ2;
- and/or carbocyclic TxA2,
- for use in treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof.
A vector comprising a nucleic acid sequence encoding a Nurr1 polypeptide for use in treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof.
A composition comprising at least one of:
- prostaglandin E (PGE) 1;
- PGE2:
- prostaglandin H(PGH)1;
- PGH2;
- PGH3;
- prostaglandin F (PFG)2a;
- prostaglandin A (PGA)1;
- PGA2;
- PGA3;
- prostaglandin B (PGB)1;
- PGB2;
- PGB3;
- PGJ2;
- 15-d-PGJ2;
- and/or carbocyclic TxA2,
- for use in treating a Nurr1-mediated and/or PPARγ-mediated condition in a subject in need thereof.
Dependencies are inferred from the claim text.